Ipsen SA
Research Ipsen SA (IPN) on Bullrun: market cap EUR 13.76B, P/E 31.4, dividend yield 1.0%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIPN
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 13.76B
- P/E31.4
- Dividend yield1.0%
- Financial periodFY2025
- RevenueEUR 3.93B
- Revenue growth9.9%
- Net incomeEUR 443.50M
- Free cash flowEUR 809.70M
- Gross margin80.9%
Valuation Snapshot
latest market cap is EUR 13.76B; P/E is 31.4; dividend yield is 1.0%.
About Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications;
Frequently asked questions
What is Ipsen SA's market cap?
Ipsen SA's market capitalization is EUR 13.76B.
What is Ipsen SA's P/E ratio?
Ipsen SA's price-to-earnings (P/E) ratio is 31.4.
Does Ipsen SA pay a dividend?
Ipsen SA has a dividend yield of 1.0%.
What does Ipsen SA do?
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications;